SCHEMBL479277

SCHEMBL479277

C=CCNC(C)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.53
CHRM2 P08172 1/20 0.53
HTR1A P08908 1/20 0.53
ADRA2A P08913 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
CHRM1 P11229 1/20 0.53
SMPD1 P17405 1/20 0.53
DRD1 P21728 1/20 0.53
TBXA2R P21731 1/20 0.53
SLC6A2 P23975 1/20 0.53
SLC6A4 P31645 1/20 0.53
ADRA1A P35348 1/20 0.53
OPRM1 P35372 1/20 0.53
DRD3 P35462 1/20 0.53
CASR P41180 1/20 0.53
HTR2B P41595 1/20 0.53
SLC6A3 Q01959 1/20 0.53
KCNH2 Q12809 1/20 0.53
LMNA P02545 1/20 0.53
CYP1A2 P05177 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1387573 1.00 CYP3A4 (0.53) CYP3A4CHRM2HTR1AADRA2AADORA3
SCHEMBL8119644 1.00 CYP3A4 (0.53) CYP3A4CHRM2HTR1AADRA2AADORA3
Hydrochloric Acid SCHEMBL11627221 0.98 CYP3A4 (0.55) CYP3A4CHRM2HTR1AADRA2AADORA3
SCHEMBL2396763 0.81 CYP3A4 (0.59) CYP3A4CHRM2HTR1AADRA2AADORA3
SCHEMBL1784975 0.81 CYP3A4 (0.59) CYP3A4CHRM2HTR1AADRA2AADORA3
SCHEMBL1357332 0.81 CYP3A4 (0.59) CYP3A4CHRM2HTR1AADRA2AADORA3
SCHEMBL10839595 0.81 GAA (0.44) CYP3A4CHRM2HTR1AADRA2AADORA3
SCHEMBL10582023 0.79 SMN1; SMN2 (0.46) CYP3A4LMNACYP2C19SMN1; SMN2KMT2A
SCHEMBL6724867 0.79 MTOR (0.58) CYP3A4LMNACYP2C19SMN1; SMN2MEN1
SCHEMBL31620151 0.78 CYP2D6 (0.55) CYP3A4CHRM2ADRA2ASLC6A4ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111193069-B Electrolyte for electrochemical device, method for preparing the same, and electrochemical device 三星电子株式会社 2024-11-01 CN claimed
US-11643398-B2 Metallic salt containing anion having heterocyclic aromatic structure, method of preparing the metallic salt, and electrolyte and electrochemical device each including the metallic salt SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-05-09 US claimed
EP-3657590-B1 METALLIC SALT CONTAINING ANION HAVING HETEROCYCLIC AROMATIC STRUCTURE, METHOD OF PREPARING THE SAME, AS WELL AS ELECTROLYTE AND ELECTROCHEMICAL DEVICE EACH INCLUDING THE METALLIC SALT SAMSUNG ELECTRONICS CO LTD (KR) 2023-04-26 EP claimed
EP-3657590-A1 METALLIC SALT CONTAINING ANION HAVING HETEROCYCLIC AROMATIC STRUCTURE, METHOD OF PREPARING THE SAME, AS WELL AS ELECTROLYTE AND ELECTROCHEMICAL DEVICE EACH INCLUDING THE METALLIC SALT Samsung Electronics Co., Ltd. (KR) 2020-05-27 EP claimed
CN-111193069-A Metal salt, method for preparing metal salt, and electrolyte and electrochemical device each containing metal salt 三星电子株式会社 2020-05-22 CN claimed
US-20200157058-A1 METALLIC SALT CONTAINING ANION HAVING HETEROCYCLIC AROMATIC STRUCTURE, METHOD OF PREPARING THE METALLIC SALT, AND ELECTROLYTE AND ELECTROCHEMICAL DEVICE EACH INCLUDING THE METALLIC SALT SAMSUNG SDI CO., LTD. (KR) 2020-05-21 US claimed
US-6060617-A REACTING AN ALKALI METAL HYDRIDE AND ALKALI METAL AMIDES WITH A SUBSTITUTED AMINE IN AN ETHER SOLVENT IN ABSENCE OF AN ELECTRON CARRIER TO PRODUCE AN ALKALI METAL AMIDE FREE OF ORGANIC CONTAMINANTS FMC CORPORATION (US) 2000-05-09 US claimed
EP-0736031-B1 IMPROVEMENTS IN OR RELATING TO CHIRAL SYNTHESES OXFORD ASYMMETRY INTERNATIONAL (GB) 2000-05-03 EP claimed
US-6037498-A Chiral syntheses OXFORD ASYMMETRY INTERNATIONAL PLC (GB) 2000-03-14 US claimed
US-5726308-A High purity formulations of highly substituted lithium amide bases FMC CORPORATION (US) 1998-03-10 US claimed
JP-H09507221-A 1997-07-22 JP claimed
WO-1995018134-A1 IMPROVEMENTS IN OR RELATING TO CHIRAL SYNTHESES OXFORD ASYMMETRY LIMITED (GB) 1995-07-06 WO claimed
EP-4747366-A1 PROCESS FOR THE REDUCTION OF AROMATIC IMINES WITH NOVEL IMINE REDUCTASES (IREDS) F. Hoffmann-La Roche AG (CH) 2026-05-27 EP disclosed
US-20260139283-A1 PROCESS FOR THE REDUCTION OF AROMATIC IMINES WITH NOVEL IMINE REDUCTASES (IREDS) HOFFMANN LA ROCHE INC (US) 2026-05-21 US disclosed
WO-2025017089-A1 PROCESS FOR THE REDUCTION OF AROMATIC IMINES WITH NOVEL IMINE REDUCTASES (IREDS) F. HOFFMANN-LA ROCHE AG (CH) 2025-01-23 WO disclosed
CN-111193069-B Electrolyte for electrochemical device, method for preparing the same, and electrochemical device 三星电子株式会社 2024-11-01 CN disclosed
US-5466798-A Reducing agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1995-11-14 US disclosed
WO-1995018134-A1 IMPROVEMENTS IN OR RELATING TO CHIRAL SYNTHESES OXFORD ASYMMETRY LIMITED (GB) 1995-07-06 WO disclosed
US-4468245-A N-(2,3-Epoxypropylene)-n-aralkylsulfonamide and herbicidal compositions containing the same MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) 1984-08-28 US disclosed
EP-0064158-A1 Omega-cyano-1, omega-diphenyl azalcane derivatives, their preparation and pharmaceutical preparations containing them BASF Aktiengesellschaft (DE) 1982-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260139283-A1 PROCESS FOR THE REDUCTION OF AROMATIC IMINES WITH NOVEL IMINE REDUCTASES (IREDS) CYP2C9, CYP1A1, CYP2E1 CYP3A4 18/4885CHRM2 1559/4885HTR1A 1291/4885
US-11643398-B2 Metallic salt containing anion having heterocyclic aromatic structure, method of preparing the metallic salt, and electrolyte and electrochemical device each including the metallic salt NAP1L1, AGTR1, AP2A1 CYP3A4 3889/4885CHRM2 404/4885HTR1A 1163/4885
US-20200157058-A1 METALLIC SALT CONTAINING ANION HAVING HETEROCYCLIC AROMATIC STRUCTURE, METHOD OF PREPARING THE METALLIC SALT, AND ELECTROLYTE AND ELECTROCHEMICAL DEVICE EACH INCLUDING THE METALLIC SALT NAP1L1, AP2A1, AGTR1 CYP3A4 3804/4885CHRM2 450/4885HTR1A 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.